ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

MRZM Marizyme Inc (QB)

0.093
0.00 (0.00%)
Jun 14 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0.00
Bid Price 0.0013
Ask Price 0.134
News -
Day High

Low
0.05

52 Week Range

High
0.405

Day Low
Share Name Share Symbol Market Stock Type
Marizyme Inc (QB) MRZM OTCMarkets Common Stock
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 0.093 15:03:40
Open Price Low Price High Price Close Price Previous Close
0.093 0.093
Trades Shares Traded Average Volume 52 Week Range
0 0.00 - 0.05 - 0.405
Last Trade Type Quantity Price Currency
- 0 US$ 0.093 USD

Marizyme Inc (QB) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
4.2M 43.42M 12.02M 646k -65.35M -1.40 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Marizyme (QB) News

Date Time Source News Article
5/28/202415:23Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
5/15/202415:05Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form..
5/13/202415:50Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K..
5/06/202416:00Edgar (US Regulatory)Form 8-K - Current report
2/06/202415:15Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]
2/06/202407:55Edgar (US Regulatory)Form 8-K - Current report
12/29/202316:15Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]
12/28/202319:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
12/28/202305:02Edgar (US Regulatory)Form 8-K - Current report
11/22/202315:36Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]
11/21/202315:15Edgar (US Regulatory)Form 8-K - Current report
11/16/202305:08Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No MRZM Message Board. Create One! See More Posts on MRZM Message Board See More Message Board Posts

Historical MRZM Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.0930.0930.0930.0935,0000.000.00%
1 Month0.090.0930.05330.09022013,9500.0033.33%
3 Months0.0950.0950.0530.07970165,691-0.002-2.11%
6 Months0.140.150.0530.0941987,692-0.047-33.57%
1 Year0.282550.4050.050.168910816,334-0.18955-67.09%
3 Years1.503.250.050.58035318,145-1.41-93.80%
5 Years0.55134.480.050.76404725,534-0.4583-83.13%

Marizyme (QB) Description

Marizyme is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical technologies that improve patient health outcomes. Currently, we are focused on developing three medical technology products -- DuraGraft, MATLOCTM and Krillase -- each of which is backed by a portfolio of patented or patent-pending assets. DuraGraft is a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure, therefore maintaining endothelial function and structure while improving clinical outcomes. MATLOC is a point-of-care, lab-on-chip digital screening and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment. Our Krillase protein enzyme provides a therapeutics opportunity for wound healing, thrombosis, and pet health.

Your Recent History

Delayed Upgrade Clock